Tekla Capital Management LLC raised its stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 59.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,706 shares of the biotechnology company’s stock after purchasing an additional 14,406 shares during the period. Tekla Capital Management LLC owned 0.10% of Spark Therapeutics worth $1,990,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its stake in shares of Spark Therapeutics by 15.0% in the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after buying an additional 241,016 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Spark Therapeutics by 6.0% in the third quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock worth $18,489,000 after buying an additional 11,785 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new position in shares of Spark Therapeutics in the third quarter worth about $5,286,000. Alyeska Investment Group L.P. purchased a new position in shares of Spark Therapeutics in the third quarter worth about $13,519,000. Finally, Principal Financial Group Inc. lifted its stake in shares of Spark Therapeutics by 23.8% in the third quarter. Principal Financial Group Inc. now owns 54,088 shares of the biotechnology company’s stock worth $4,822,000 after buying an additional 10,399 shares in the last quarter.
Several research firms have recently weighed in on ONCE. BMO Capital Markets set a $64.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 21st. ValuEngine raised shares of Spark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, March 1st. Credit Suisse Group reissued an “outperform” rating and issued a $75.00 price target (up from $61.00) on shares of Spark Therapeutics in a research note on Thursday, March 8th. Raymond James Financial set a $66.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Finally, Mizuho restated a “buy” rating and set a $79.00 price objective on shares of Spark Therapeutics in a research report on Wednesday, February 21st. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the company’s stock. Spark Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $70.58.
Shares of Spark Therapeutics Inc (NASDAQ ONCE) traded up $2.61 on Friday, hitting $67.51. 972,279 shares of the company’s stock were exchanged, compared to its average volume of 732,536. Spark Therapeutics Inc has a 1-year low of $41.06 and a 1-year high of $91.75. The firm has a market capitalization of $2,415.42, a PE ratio of -8.73 and a beta of 2.82.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.73). Spark Therapeutics had a negative net margin of 2,100.80% and a negative return on equity of 59.38%. The business had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $9.53 million. sell-side analysts anticipate that Spark Therapeutics Inc will post -3.42 earnings per share for the current year.
WARNING: “Tekla Capital Management LLC Increases Position in Spark Therapeutics Inc (NASDAQ:ONCE)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/17/spark-therapeutics-inc-once-holdings-lifted-by-tekla-capital-management-llc.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.